MAIA Biotechnology Announces Expansion of Clinical Supply Agreement with Regeneron for Phase 2 Trial in Non-Small Cell Lung ...

This page includes links to articles highlighting the top lung cancer research published on Cancer Therapy Advisor in 2024.

The first computer algorithm capable of identifying which tumor cells are driving aggressive cancer growth has been developed ...

Merck ( MRK, Financials) stated that sacituzumab tirumotecan (sac-TMT) was designated a Breakthrough Therapy by the FDA for advanced or metastatic nonsquamous non-small cell lung cancer with epidermal ...

The first computer algorithm capable of identifying which tumor cells are driving aggressive cancer growth has been developed by Cancer Research UK-funded scientists from UCL and The Francis Crick ...

The FDA has granted Breakthrough Therapy designation to sacituzumab tirumotecan for patients with advanced or metastatic ...

Merck & Co., Inc. (MRK) announced Tuesday that the U.S. Food and Drug Administration has granted Breakthrough Therapy designation to ...

Merck's (MRK) antibody drug conjugate sac-TMT has received FDA Breakthrough Therapy designation for the treatment of EGFR-mutated lung cancer. Read more here.

Guggenheim analyst Michael Schmidt raised the firm’s price target on Revolution Medicines (RVMD) to $87 from $82 and keeps a Buy rating on the ...

A study from the University of Michigan Health Rogel Cancer Center may have—at last—cracked the cold case of immunotherapy ...

In patients with advanced solid tumors, treatment with nemvaleukin with or without Keytruda demonstrated antitumor activity ...

Gilead isn’t the only Big Pharma to take an interest in Tubulis’ ADC tech. BMS paid the company $23 million upfront in April ...